The immune cell therapy currently in clinical application basically uses the patient's autologous immune cells as raw materials. Immune cell products from autologous sources are highly individualized, with limited production scale, difficult quality control, and long preparation cycles. In addition, patients with rapid disease progression cannot benefit from it, and it is difficult to achieve the standardization and industrialization of immune cell therapy. Therefore, the development of allogeneic cell therapy products has become one of the main directions in the field of tumor immune cell therapy.
Human iPSC has unlimited proliferation and directed differentiation potential. Based on these features, iPSC provides a new perspective for the production of CAR-NK cells. Firstly, the iPSC can be used to mass-produce CAR-NK cells with uniform and controllable quality to solve the problem of the quantity and dosage of primary immune cell products. Secondly, iPSC can be easily engineered in vitro to enhance the applicability, potency and durability of CAR-NK cells. Finally, the fully evaluated and engineered iPSC can be used as a seed source for various immune cell products, helping to develop "off-the-shelf" cell therapies for more patients and malignant tumor types.
Internationally, Fate Therapeutics (United States) currently has 4 iPSC-derived CAR-NK cell products that have been approved by the FDA to enter phase I clinical trials for the treatment of acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), B-cell lymphoma (BCL), multiple myeloma (MM), and advanced solid tumors.
Reference source: Fate Therapeutics official website
Nuwacell Biotechnologies Co., Ltd. has established a human immune cell research and development and production platform, and established a standardized immune cell activation, amplification, activity and function detection system using effective gene editing system.
The CAR-T, allogeneic NK, iCAR-T, and iNK cell products, originally developed by Nuwacell Biotechnologies Co., Ltd. are fully verifying the killing ability and safety of tumor cells. Nuwacell Biotechnologies Co., Ltd. will continue to promote the development of CAR-T, allogeneic NK, iCAR-T, and iNK cell drugs to benefit cancer patients as soon as possible.